This creates an a priori case for using drugs that attenuate deterioration of renal function e.g. as ACE-inhibitors, angiotensin receptor blockers [40] and/or SGLT2 inhibitors [41] to reduce HF incidence in patients with persistent obesity. The gene discussed is ACE; the disease is Obesity.